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FACTS FOR COMMUNITY MEMBERS 
SCOPE OF THE PROBLEM 
Opioid overdose continues to be a major public health problem in the United States. It has contributed significantly to accidental deaths among those who 
use or misuse illicit and prescription opioids. In fact, U.S. 
overdose deaths involving prescription opioid analgesics 
increased to about 19,000 deaths in 20141,2 more than three 
times the number in 2001.1 According to Centers for Disease 
Control and Prevention (CDC) data, health care providers 
wrote 259 million prescriptions for painkillers in 2012, enough 
for every American adult to have a bottle of pills.3-4  
WHAT ARE OPIOIDS? Opioids include illegal drugs such 
as heroin, as well as prescription medications used to treat 
pain such as morphine, codeine, methadone, oxycodone 
(OxyContin®, Percodan®, Percocet®), hydrocodone 
(Vicodin®, Lortab®, Norco®), fentanyl (Duragesic®, 
Fentora®), hydromorphone (Dilaudid®, Exalgo®), and 
buprenorphine (Subutex®, Suboxone®). 
Opioids work by binding to specific receptors in the brain, 
spinal cord, and gastrointestinal tract. In doing so, they 
minimize the body’s perception of pain. However, stimulating 
the opioid receptors or “reward centers” in the brain can also 
trigger other systems of the body, such as those responsible 
for regulating mood, breathing, and blood pressure. 
HOW DOES OVERDOSE OCCUR? A variety of effects 
can occur after a person takes opioids, ranging from 
pleasure to nausea, vomiting, severe allergic reactions 
(anaphylaxis), and overdose, in which breathing and 
heartbeat slow or even stop. 
Opioid overdose can occur when a patient deliberately 
misuses a prescription opioid or an illicit drug such as heroin. 
It can also occur when a patient takes an opioid as directed, 
but the prescriber miscalculated the opioid dose or an error 
was made by the dispensing pharmacist or the patient 
misunderstood the directions for use. 
Also at risk are individuals who misuse opioids and 
combine them with sedative hypnotic agents resulting in 
sedation and respiratory depression.5,6
WHO IS AT RISK? Anyone who uses 
opioids for long-term management of 
chronic cancer or non-cancer pain is at 
risk for opioid overdose, as are persons 
who use heroin.7 Others at risk include 
persons who are: 
 Receiving rotating opioid medication
regimens (and thus are at risk for
incomplete cross-tolerance).
 Discharged from emergency medical
care following opioid intoxication or
poisoning.
 At high risk for overdose because of
a legitimate medical need for
analgesia, coupled with a suspected
or confirmed substance use disorder,
or non-medical use of prescription or
illicit opioids.
 Completing mandatory opioid
detoxification or abstinent for a period
of time (and presumably with reduced
opioid tolerance and high risk of
relapse to opioid use).
 Recently released from incarceration
and who have a history of opioid use
disorder (and presumably have
reduced opioid tolerance and high
risk of relapse to opioid use).
Tolerance develops when someone uses 
an opioid drug regularly, so that their 
body becomes accustomed to the drug 
and needs a larger or more frequent 
dose to continue to experience the 
same effect. 
Loss of tolerance occurs when someone 
stops taking an opioid after long-term 
use. When someone loses tolerance and 
then takes the opioid drug again, they 
can experience serious adverse effects, 
including overdose, even if they take an 
amount that caused them no problem in 
the past. 
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STRATEGIES TO PREVENT OVERDOSE DEATHS 
STRATEGY 1: Encourage providers, persons at high risk, family members, 
and others to learn how to prevent and manage opioid overdose. Providers 
should be encouraged to keep their knowledge current about evidence-based practices 
for the use of opioid analgesics to manage pain, as well as specific steps to prevent and 
manage opioid overdose. 
Federally funded Continuing Medical Education courses are available to providers 
at no charge at http://www.OpioidPrescribing.com (a series of courses funded by the 
Substance Abuse and Mental Health Services Administration [SAMHSA]). 
Helpful information for laypersons on how to prevent and manage overdose is 
available from Project Lazarus at http://www.projectlazarus.org or from the 
Massachusetts Health Promotion Clearinghouse at http://www.maclearinghouse.org. 
STRATEGY 2: Ensure access to treatment for individuals who are misusing or 
addicted to opioids or who have other substance use disorders. Effective 
treatment of substance use disorders can reduce the risk of overdose and help 
overdose survivors attain a healthier life. Medication-assisted treatment, as well as 
counseling and other supportive services, can be obtained at SAMHSA-certified and 
Drug Enforcement Administration (DEA)-registered opioid treatment programs (OTPs), 
as well as from physicians who are trained to provide care in office-based settings with 
medications such as buprenorphine and naltrexone. 
Information on treatment services available in or near your community can be obtained 
from your state health department, your state alcohol and drug agency, or SAMHSA 
(see page 4). 
STRATEGY 3: Ensure ready access to naloxone. Opioid overdose-related deaths 
can be prevented when naloxone is administered in a timely manner. As a narcotic 
antagonist, naloxone displaces opiates from receptor sites in the brain and reverses 
respiratory depression that usually is the cause of overdose deaths.7
On the other hand, naloxone is not effective in treating overdoses of 
benzodiazepines (such as Valium®, Xanax®, or Klonopin®), barbiturates (Seconal® or 
Fiorinal®), clonidine, Elavil®, GHB, ketamine, or synthetics. It is also not effective in 
overdoses with stimulants, such as cocaine and amphetamines (including 
methamphetamine and Ecstasy). However, if opioids are taken in combination with 
other sedatives or stimulants, naloxone may be helpful. 
Naloxone injection has been approved by the United States Food and Drug 
Administration (FDA) and used for more than 40 years by emergency medical services 
(EMS) personnel to reverse opioid overdose and resuscitate persons who otherwise 
might have died in the absence of treatment.8
Encourage
to learn 
about
managing
opioid 
overdose 
Ensure 
access to 
treatment
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Naloxone does not have the potential for abuse. It reverses the effects of 
opioid overdose.9 Injectable naloxone is relatively inexpensive. It typically is 
supplied as a kit with two syringes10 These kits require training on how to 
administer naloxone using a syringe. The FDA has also approved an intranasal 
naloxone product, called Narcan® Nasal Spray, and a naloxone auto-injector, 
called Evzio®. The intranasal spray is a pre-filled, needle-free device that requires 
no assembly. The auto-injector can deliver a dose of naloxone through clothing, if 
necessary, when placed on the outer thigh.  
Prior to 2012, just six states had any laws that expanded access to naloxone 
or limited criminal liability.11 Today, 42 states and the District of Columbia have 
statutes that provide criminal liability protections to laypersons or first responders 
who administer naloxone. Thirty-nine states and the District of Columbia have 
statutes that provide civil liability protections to laypersons or first responders who 
administer naloxone. Thirty-eight states have statutes that offer criminal liability 
protections for prescribing or distributing naloxone. Thirty-three states have 
statutes that offer civil liability protections for prescribing or distributing naloxone. 
And 42 states have statutes that allow naloxone distribution to third parties or first 
responders via direct prescription or standing order. To find states that have 
adopted relevant laws, visit the White House website at 
https://www.whitehouse.gov/sites/default/files/ondcp/Blog/
naloxonecirclechart_january2016.pdf. 
STRATEGY 4: Encourage the public to call 911. An individual who is 
experiencing opioid overdose needs immediate medical attention. An essential 
first step is to get help from someone with medical expertise as quickly as 
possible.12-13 Therefore, members of the public should be encouraged to call 911. 
All they have to say is “Someone is not breathing” and give a clear address and 
location. Thirty-two states and the District of Columbia have “Good Samaritan” 
statutes that prevent arrest, charge, or prosecution for possession of a controlled 
substance or paraphernalia if emergency assistance is sought for someone who is 
experiencing an opioid-induced overdose. 
STRATEGY 5: Encourage prescribers to use state Prescription Drug 
Monitoring Programs. State Prescription Drug Monitoring Programs (PDMPs) 
have emerged as a key strategy for addressing the misuse of prescription opioids 
and thus preventing opioid overdoses and deaths. Specifically, prescribers can 
check their state’s PDMP database to determine whether a patient is filling the 
prescriptions provided and/or obtaining prescriptions for the same or a similar 
drug from multiple prescribers. 
While nearly all states now have operational PDMPs, the programs differ from 
state to state in terms of the exact information collected, how soon that 
information is available to prescribers, and who may access the data. Therefore, 
information about the program in a particular state is best obtained directly from 
the state PDMP or from the board of medicine or pharmacy. 
Encourage 
the public to 
call 911. 
Encourage 
prescribers 
to use state 
Prescription 
Drug 
Monitoring 
Programs. 
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RESOURCES FOR COMMUNITIES  
Resources that may be useful to local communities and organizations are found 
at:  
Substance Abuse and Mental Health Services Administration (SAMHSA) 
 National Helpline: 
1-800-662-HELP (4357) or 1-800-487-4889 (TDD — for hearing impaired) 
 Behavioral Health Treatment Locator:  
https://findtreatment.samhsa.gov to search by address, city, or zip code 
 Buprenorphine Treatment Physician Locator: 
http://www.samhsa.gov/medication-assisted-treatment/physician-program-
data/treatment-physician-locator 
 State Substance Abuse Agencies: 
https://findtreatment.samhsa.gov/TreatmentLocator/faces/about.jspx 
 Center for Behavioral Health Statistics and Quality (CBHSQ):  
http://www.samhsa.gov/data  
 SAMHSA Publications: http://store.samhsa.gov  
1-877-SAMHSA (1-877-726-4727) 
Centers for Disease Control and Prevention (CDC)  
http://www.cdc.gov/drugoverdose/epidemic 
http://www.cdc.gov/homeandrecreationalsafety/poisoning 
White House Office of National Drug Control Policy (ONDCP) 
State and Local Information: http://www.whitehouse.gov/ondcp/state-map 
Association of State and Territorial Health Officials  
(ASTHO) ASTHO 214 Policy Inventory: State Action to Prevent and Treat 
Prescription Drug Abuse: http://www.astho.org/rx/profiles/Rx-Survey-Highlights  
National Association of State Alcohol and Drug Abuse Directors 
(NASADAD)  
Overview of State Legislation to Increase Access to Treatment for Opioid 
Overdose:  
http://nasadad.org/wp-content/uploads/2015/09/Opioid-Overdose-Policy-Brief-
2015-Update-FINAL1.pdf 
American Association for the Treatment of Opioid Dependence (AATOD) 
Prevalence of Prescription Opioid Abuse:  
http://www.aatod.org/projectseducational-training/prevalance-of-prescription-
opioid-abuse  
Resources 
that may be 
useful to 
local 
communities 
and 
organizations
… 
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FIVE ESSENTIAL STEPS FOR FIRST RESPONDERS 
Overdose is common among persons who use illicit opioids such 
as heroin and among those 
who misuse medications 
prescribed for pain, such as 
oxycodone, hydrocodone, and 
morphine. The incidence of 
opioid overdose is rising 
nationwide. In 2014, 28,647 of 
drug overdose deaths involved 
some type of opioid, including 
heroin.14 U.S. overdose 
deaths involving prescription 
opioid analgesics increased to 
about 19,000 deaths in 20141,2 
more than three times the 
number in 2001.1
To address the problem, 
emergency medical personnel, 
health care professionals, and 
patients increasingly are being 
trained in the use of the opioid 
antagonist naloxone 
hydrochloride (naloxone), 
which is the treatment of 
choice to reverse the 
potentially fatal respiratory 
depression caused by opioid 
overdose. (Note that naloxone 
has no effect on non-opioid 
overdoses, such as those 
involving cocaine, 
benzodiazepines, or 
alcohol.)15
The steps outlined below 
are recommended to reduce 
the number of deaths resulting 
from opioid 
overdoses2,6,10,16,17,18,19,20
STEP 1: CALL FOR HELP (DIAL 911) 
AN OPIOID OVERDOSE NEEDS IMMEDIATE MEDICAL 
ATTENTION. An essential step is to get someone with medical 
expertise to see the patient as soon as possible, so if no emergency 
medical services (EMS) or other trained personnel are on the scene, 
dial 911 immediately. All you have to say is “Someone is not 
breathing.” Be sure to give a clear address and/or description of your 
location. 
STEP 2: CHECK FOR SIGNS OF 
OPIOID OVERDOSE 
Signs of OVERDOSE, which often results in death if not treated, 
include15: 
 Extreme sleepiness, inability to awaken verbally or upon 
sternal rub. 
 Breathing problems that can range from slow to shallow 
breathing in a patient that cannot be awakened. 
 Fingernails or lips turning blue/purple. 
 Extremely small “pinpoint” pupils. 
 Slow heartbeat and/or low blood pressure. 
Signs of OVERMEDICATION, which may progress to overdose, 
include:15
 Unusual sleepiness, drowsiness, or difficulty staying awake 
despite loud verbal stimulus or vigorous sternal rub. 
 Mental confusion, slurred speech, intoxicated behavior. 
 Slow or shallow breathing. 
 Extremely small “pinpoint” pupils, although normal size pupils 
do not exclude opioid overdose. 
 Slow heartbeat, low blood pressure. 
 Difficulty waking the person from sleep. 
Because opioids depress respiratory function and breathing, one 
telltale sign of a person in a critical medical state is the “death rattle.” 
If a person emits a “death rattle”—an exhaled breath with a very 
distinct, labored sound coming from the throat—emergency 
resuscitation will be necessary immediately, as such a sound almost 
always is a sign that the individual is near death.17 
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STEP 3: SUPPORT THE PERSON’S 
BREATHING 
Ventilatory support is an important intervention and may be life-
saving on its own. Patients should be ventilated with oxygen prior to 
administration of naloxone.2,6 In situations where oxygen is not 
available, rescue breathing can be very effective in supporting 
respiration.2 Rescue breathing for adults involves the following steps: 
 Be sure the person’s airway is clear (check that nothing inside 
the person’s mouth or throat is blocking the airway). 
 Place one hand on the person’s chin, tilt the head back and 
pinch the nose closed. 
 Place your mouth over the person’s mouth to make a seal 
and give 2 slow breaths. 
 The person’s chest should rise (but not the stomach). 
 Follow up with one breath every 5 seconds. 
STEP 4: ADMINISTER NALOXONE  
Any patient who presents with signs of opioid overdose, or when 
this is suspected, should be administered naloxone. Naloxone 
injection is approved by the FDA and has been used for decades by 
EMS personnel to reverse opioid overdose and resuscitate 
individuals who have overdosed on opioids. 
Naloxone can be given by intranasal spray, intramuscular (into 
the muscle), subcutaneous (under the skin), or intravenous 
injection.17-19 The most rapid onset of action is achieved by 
intravenous administration, which is recommended in emergency 
situations.17 The dose should be titrated to the smallest effective dose 
that maintains spontaneous normal respiratory drive. 
Opioid-naive patients may be given starting doses of up to 2 mg 
without concern for triggering withdrawal symptoms depending on the 
route of administration.2,9,18
The intramuscular route of administration for naloxone may be 
suitable for patients with suspected opioid use disorder because it 
provides a slower onset of action and a prolonged duration of effect, 
which may minimize rapid onset of withdrawal symptoms.2,5,10
DURATION OF EFFECT. The duration of effect of naloxone is 20 to 
90 minutes depending on dose and route of administration6, and 
overdose symptoms.5,17,18 The goal of naloxone therapy should be to 
restore adequate spontaneous breathing, but not necessarily 
complete arousal.5
                                                          
More than one dose of 
naloxone may be needed to 
revive someone who is 
overdosing. Patients who have 
taken longer-acting opioids 
may require further 
intravenous bolus doses or an 
infusion of naloxone.21
Comfort the person being 
treated, as withdrawal 
triggered by naloxone can feel 
unpleasant. As a result, some 
persons become agitated or 
combative when this happens 
and need help to remain calm. 
SAFETY OF NALOXONE. 
The safety profile of naloxone 
is remarkably high, especially 
when used in low doses and 
titrated to effect.2,9,17,22  When 
given to individuals who are 
not opioid-intoxicated or 
opioid-dependent, naloxone 
produces no clinical effects, 
even at high doses. Moreover, 
although rapid opioid 
withdrawal in tolerant patients 
may be unpleasant, it is not 
life-threatening. 
Naloxone can be used in 
life-threatening opioid 
overdose circumstances in 
pregnant women.23
The FDA has approved 
injectable naloxone, intranasal 
naloxone (called Narcan® 
Nasal Spray), and a naloxone 
auto-injector (called Evzio®1). 
1 http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm391465.htm 
The currently available 
naloxone kits that include a 
syringe and naloxone ampules 
or vials or a prefilled naloxone 
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syringe and a mucosal atomizer device to enable intranasal delivery 
require the user to be trained on how to assemble all of the materials 
and administer the naloxone to the victim. The Narcan Nasal Spray is 
a pre-filled, needle-free device that requires no assembly, which can 
deliver a single dose into one nostril. The Evzio auto-injector is 
injected into the outer thigh to deliver naloxone to the muscle 
(intramuscular) or under the skin (subcutaneous). Once turned on, 
the device provides verbal instruction to the user describing how to 
deliver the medication, similar to automated defibrillators. Both 
Narcan Nasal Spray and Evzio are packaged in a carton containing 
two doses, to allow for repeat dosing if needed. 
STEP 5: MONITOR THE PERSON’S 
RESPONSE 
All patients should be monitored for recurrence of signs and 
symptoms of opioid toxicity for at least 4 hours from the last dose of 
naloxone or discontinuation of the naloxone infusion. Patients who 
have overdoses on long-acting opioids should have more prolonged 
monitoring.2,10
Most patients respond by returning to spontaneous breathing. 
The response generally occurs within 3 to 5 minutes of naloxone 
administration. (Continue rescue breathing while waiting for the 
naloxone to take effect.)2,5,10
Naloxone will continue to work for 30 to 90 minutes, but after that 
time, overdose symptoms may return.17,18Therefore, it is essential to 
get the person to an emergency department or other source of 
medical care as quickly as possible, even if he or she revives after 
the initial dose of naloxone and seems to feel better. 
SIGNS OF OPIOID WITHDRAWAL. The signs and symptoms of 
opioid withdrawal in an individual who is physically dependent on 
opioids may include, but are not limited to, the following: body aches, 
diarrhea, tachycardia, fever, runny nose, sneezing, piloerection, 
sweating, yawning, nausea or vomiting, nervousness, restlessness or 
irritability, shivering or trembling, abdominal cramps, weakness, and 
increased blood pressure. In the neonate, opioid withdrawal may also 
include convulsions, excessive crying, and hyperactive reflexes.17
NALOXONE NON-
RESPONDERS. If a patient 
does not respond to naloxone, 
an alternative explanation for 
the clinical symptoms should 
be considered. The most likely 
explanation is that the person 
is not overdosing on an opioid 
but rather some other 
substance or may even be 
experiencing a non-overdose 
medical emergency. A 
possible explanation to 
consider is that the individual 
has overdosed on 
buprenorphine, a long-acting 
opioid partial agonist. Because 
buprenorphine has a higher 
affinity for the opioid receptors 
than do other opioids, 
naloxone may not be effective 
at reversing the effects of 
buprenorphine-induced opioid 
overdose.18
In all cases, support of 
ventilation, oxygenation, and 
blood pressure should be 
sufficient to prevent the 
complications of opioid 
overdose and should be given 
priority if the response to 
naloxone is not prompt. 
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SUMMARY 
Do’s and Don’ts in Responding to Opioid Overdose 
 DO support the person’s breathing by administering oxygen or performing rescue breathing. 
 DO administer naloxone. 
 DO put the person in the “recovery position” on the side, if he or she is breathing independently. 
 DO stay with the person and keep him/her warm. 
 DON’T slap or try to forcefully stimulate the person—it will only cause further injury. If you are unable 
to wake the person by shouting, rubbing your knuckles on the sternum (center of the chest or rib 
cage), or light pinching, he or she may be unconscious. 
 DON’T put the person into a cold bath or shower. This increases the risk of falling, drowning, or 
going into shock. 
 DON’T inject the person with any substance (saltwater, milk, “speed,” heroin, etc.). The only safe 
and appropriate treatment is naloxone. 
 DON’T try to make the person vomit drugs that he or she may have swallowed. Choking or inhaling 
vomit into the lungs can cause a fatal injury. 
NOTE: All naloxone products have an expiration date, so it is important to check the expiration date and 
obtain replacement naloxone as needed. 
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Opioid overdose is a major public health problem. In 2014, 28,647 of drug overdose deaths involved some type of opioid, including heroin.14,19 Overdose involves both men 
and women of all ages, ethnicities, and demographic and 
economic characteristics, and involves both illicit opioids such as 
heroin and, increasingly, prescription opioid analgesics such as 
oxycodone, hydrocodone, fentanyl, and methadone.4
Physicians and other health care providers can make a 
major contribution toward reducing the toll of opioid overdose 
through the care they take in prescribing opioid analgesics and 
monitoring patients’ response, as well as through their acuity in 
identifying and effectively addressing opioid overdose. Federally 
funded Continuing Medical Education (CME) courses are 
available at no charge at http://www.OpioidPrescribing.com (a 
series of courses funded by the Substance Abuse and Mental 
Health Services Administration [SAMHSA])2. 
2 For additional educational material for extended-release and long-acting opioid analgesics, see  
http://www.er-la-opioidrems.com/IwgUI/rems/faq.action and the FDA Blueprint for Prescriber 
Education for Extended- Release and Long-Acting Opioid Analgesics, 
http://www.accessdata.fda.gov/drugsatfda_docs/rem
s/ERLA_opioids_2015-10-23_FDA_Blueprint.pdf
OPIOID OVERDOSE 
The risk of opioid overdose can be minimized through 
adherence to the following clinical practices, which are supported 
by a considerable body of evidence. 2,10,22,24
ASSESS THE PATIENT. Obtaining a history of the patient’s 
past use of drugs (either illicit drugs or prescribed medications 
with misuse potential) is an essential first step in appropriate 
prescribing. Such a history should include very specific 
questions. For example: 
 “In the past 6 months, have you taken any medications to 
help you calm down, keep from getting nervous or upset, 
raise your spirits, make you feel better, and the like?” 
 “Have you been taking any medications to help you sleep? 
Have you been using alcohol for this purpose?” 
 “Have you ever taken a medication to help you with a drug 
or alcohol problem?” 
 “Have you ever taken a medication for a nervous 
stomach?” 
 “Have you taken a medication to give you more energy or 
to cut down on your appetite?” 
 “Have you ever been treated for a possible or suspected 
opioid overdose?” 
                                                          
The patient history should also 
include questions about use of 
alcohol and over-the- counter 
(OTC) preparations. For example, 
the ingredients in many common 
cold preparations include alcohol 
and other central nervous system 
(CNS) depressants, so these 
products should not be used in 
combination with opioid analgesics. 
Positive answers to any of 
these questions warrant further 
investigation. 
TAKE SPECIAL PRECAUTIONS 
WITH NEW PATIENTS. Many 
experts recommend that additional 
precautions be taken in pre- 
scribing opioid analgesics for new 
patients.22 These might involve the 
following: 
1. Assessment: In addition to doing 
the patient history and 
examination, the physician 
should determine who has been 
caring for the patient in the past, 
what medications have been 
prescribed and for what 
indications, what substances 
(including alcohol, illicit drugs, 
and OTC products) the patient 
has reported using, and when 
and what amount was last used 
and by what route. Medical 
records should be obtained (with 
the patient’s consent). 
2. Emergencies: In emergency 
situations, the physician should 
prescribe the smallest possible 
quantity, typically not exceeding 
3 days’ supply, and arrange for a 
. 
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return visit the next day. In addition, consider prescribing 
naloxone to help mitigate risk associated with these emergent 
situations. At a minimum, the patient’s identity should be 
verified by asking for proper identification. 
3. Non-emergencies: In non-emergency situations, only enough 
of an opioid analgesic should be prescribed to meet the 
patient’s needs until the next appointment. The patient should 
be directed to return to the office for additional prescriptions, 
as telephone orders do not allow the physician to reassess the 
patient’s continued need for the medication. 
STATE PRESCRIPTION DRUG MONITORING 
PROGRAMS. State Prescription Drug Monitoring Programs 
(PDMPs) have emerged as a key strategy for addressing the 
misuse of prescription opioids and thus preventing opioid 
overdoses and deaths. Specifically, prescribers can check their 
state’s PDMP database to determine whether a patient is filling 
the prescriptions provided and/or obtaining prescriptions for the 
same or similar drugs from multiple physicians. 
While nearly all states now have operational PDMPs, the 
programs differ from state to state in terms of the exact 
information collected, how soon that information is available to 
physicians, and who may access the data. Therefore, 
information about the program in a particular state is best 
obtained directly from the PDMP or from the state board of 
medicine or pharmacy. 
SELECT AN APPROPRIATE MEDICATION. Rational drug 
therapy demands that the efficacy and safety of all potentially 
useful medications be reviewed for their relevance to the 
patient’s disease or disorder.2,22
When an appropriate medication has been selected, the 
dose, schedule, and formulation should be determined. These 
choices often are just as important in optimizing 
pharmacotherapy as the choice of medication itself. Decisions 
involve (1) dose (based not only on age and weight of the 
patient, but also on severity of the disorder, possible loading-
dose requirement, and the presence of potentially interacting 
drugs); (2) timing of administration (such as a bedtime dose to 
minimize problems associated with sedative or respiratory 
depressant effects); (3) route of administration (chosen to 
improve compliance/adherence as well as to attain peak drug 
concentrations rapidly); and (4) formulation (e.g., selecting a 
patch in preference to a tablet, or an extended-release product 
rather than an immediate-release formulation). 
Even when sound medical 
indications have been established, 
physicians typically consider three 
additional factors before deciding 
to prescribe an opioid analgesic2,22: 
1. The severity of symptoms, in 
terms of the patient’s ability to 
accommodate them. Relief of 
symptoms is a legitimate goal 
of medical practice, but using 
opioid analgesics requires 
caution. 
2. The patient’s reliability in taking 
medications, noted through 
observation and careful history-
taking. The physician should 
assess a patient’s history of 
and risk factors for substance 
use disorders before 
prescribing any psychoactive 
drug and weigh the benefits 
against the risks. The likely 
development of physical 
dependence in patients on 
long-term opioid therapy should 
be monitored through periodic 
checkups. 
3. The dependence-producing 
potential of the medication. The 
physician should consider 
whether a product with less 
potential for misuse, or even a 
non-drug therapy, would 
provide equivalent benefits. 
Patients should be warned 
about possible adverse effects 
caused by inter- actions 
between opioids and other 
medications or substances, 
including alcohol. At the time a 
drug is prescribed, patients 
should be informed that it is 
illegal to sell, give away, or 
otherwise share their 
medication with others, 
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including family members. The patient’s obligation extends to 
keeping the medication in a locked cabinet or otherwise 
restricting access to it and to safely disposing of any unused 
supply (visit http://www.fda.gov/ForConsumers/Consumer-
Updates/ucm101653.htm for advice from the United States 
Food and Drug Administration (FDA) on how to safely 
dispose of unused medications). 
EDUCATE THE PATIENT AND OBTAIN INFORMED 
CONSENT. Obtaining informed consent involves informing the 
patient about the risks and benefits of the proposed therapy and 
of the ethical and legal obligations such therapy imposes on 
both physician and patient.22 Such informed consent can serve 
multiple purposes: (1) it provides the patient with information 
about the risks and benefits of opioid therapy; (2) it fosters 
adherence to the treatment plan; it limits the potential for 
inadvertent drug misuse; and (4) it improves the efficacy of the 
treatment program. 
Patient education and informed consent should specifically 
address the potential for physical dependence and cognitive 
impairment as side effects of opioid analgesics.3
3 An important source of patient information is the FDA package insert. The medication guides
that accompany all extended-release or long-acting as well as oral solution opioids should be 
reviewed as part of the FDA Risk Evaluation and Management Strategy (REMS). For links to 
medication guides, please visit http://www.er-la-opioidrems.com/IwgUI/rems/products.action.    
For a general patient counseling document on opioid 
analgesics, available in English or Spanish, please 
visit: http://www.er-la-
opioidrems.com/IwgUI/rems/pcd.action
Other issues that should be addressed in the informed consent 
or treatment agreement include the following22: 
 The agreement instructs the patient to stop taking all other
pain medications, unless explicitly told to continue by the
physician. Such a statement reinforces the need to adhere to
a single treatment regimen.
 The patient agrees to obtain the prescribed medication from
only one physician and, if possible, from one designated
pharmacy.
 The patient agrees to take the medication only as prescribed
(for some patients, it may be possible to offer latitude to
adjust the dose as symptoms dictate).
 The agreement makes it clear that the patient is responsible
for safeguarding the written prescription and the supply of
medications, and arranging refills during regular office hours.
This responsibility includes planning ahead so as not to run
out of medication during weekends or vacation.
 The agreement specifies the consequences for failing to ad- 
here to the treatment plan, which may include
discontinuation of opioid 
therapy if the patient’s actions 
compromise his or her safety. 
Both patient and physician 
should sign the informed con- sent 
agreement, and a copy should be 
placed in the patient’s medical 
record. It also is helpful to give the 
patient a copy of the agreement to 
carry with him or her, to document 
the source and reason for any 
controlled drugs in his or her 
possession. 
Some physicians provide a 
laminated card that identifies the 
individual as a patient of their 
practice. This is helpful to other 
physicians who may see the 
patient and in the event the patient 
is seen in an emergency 
department. 
EXECUTE THE PRESCRIPTION 
ORDER. Careful execution of the 
prescription order can prevent 
manipulation by the patient or 
others intent on obtaining opioids 
for non-medical purposes. For 
example, federal law requires that 
prescription orders for controlled 
substances be signed and dated 
on the day they are issued. Also 
under federal law, every 
prescription or der must include at 
least the following information: 
 Name and address of the
patient
 Name, address, and DEA
registration number of the
physician
.
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 Signature of the physician 
 Name and quantity of the drug prescribed 
 Directions for use 
 Refill information 
 Effective date if other than the date on which the prescription 
was written 
Many states impose additional requirements, which the 
physician can determine by consulting the state medical 
licensing board. In addition, there are special federal 
requirements for drugs in different schedules of the federal 
Controlled Substances Act (CSA), particularly those in Schedule 
II, where many opioid analgesics are classified. 
Blank prescription pads as well as information such as the 
names of physicians who recently retired, left the state, or died 
all can be used to forge prescriptions. Therefore, it is a sound 
practice to store blank prescriptions in a secure place rather than 
leaving them in examining rooms. 
NOTE: The physician should immediately report the theft or loss 
of prescription blanks to the nearest field office of the federal 
Drug Enforcement Administration and to the state board of 
medicine or pharmacy. 
MONITOR THE PATIENT’S RESPONSE TO TREATMENT. 
Proper prescription practices do not end when the patient 
receives a prescription. Plans to monitor for drug efficacy and 
safety, compliance, and potential development of tolerance must 
be documented and clearly communicated to the patient.2
Subjective symptoms are important in monitoring, as are 
objective clinical signs (such as body weight, pulse rate, 
temperature, blood pressure, and levels of drug metabolites in 
the bloodstream). These can serve as early signs of therapeutic 
failure or unacceptable adverse drug reactions that require 
modification of the treatment plan. 
Asking the patient to keep a log of signs and symptoms gives 
him or her a sense of participation in the treatment program and 
facilitates the physician’s review of therapeutic progress and 
adverse events. 
Simply recognizing the potential for non-adherence, 
especially during prolonged treatment, is a significant step 
toward improving medication use25. Steps such as simplifying 
the drug regimen and offering patient education also improve 
adherence, as do phone calls to patients, home visits by nursing 
personnel, convenient packaging of medication, and periodic 
urine testing for the prescribed 
opioid as well as any other 
respiratory depressant. 
Finally, the physician should 
convey to the patient through 
attitude and manner that any 
medication, no matter how helpful, 
is only part of an overall treatment 
plan. 
When the physician is 
concerned about the behavior or 
clinical progress (or lack thereof) of 
a patient being treated with an 
opioid analgesic, it usually is 
advisable to seek a consultation 
with an expert in the disorder for 
which the patient is being treated 
and an expert in addiction. 
Physicians place themselves at risk 
if they continue to prescribe opioids 
in the absence of such 
consultations.22
CONSIDER PRESCRIBING 
NALOXONE ALONG WITH THE 
PATIENT’S INITIAL OPIOID 
PRESCRIPTION. Naloxone 
competitively binds opioid 
receptors and is the antidote to 
acute opioid toxicity. With proper 
education, patients on long-term 
opioid therapy and others at risk for 
overdose may benefit from being 
prescribed (1) a naloxone kit 
containing naloxone, syringes, and 
needles; (2) Narcan® Nasal Spray, 
which delivers a single dose of 
naloxone into one nostril via a pre-
filled intranasal spray; or (3) 
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Evzio®,4 which delivers a single dose of naloxone to the outer 
thigh via a hand-held auto-injector. 5,9
4 For further information about Evzio® visit 
http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm. 
Patients who are candidates for such kits include those who are: 
 Taking high doses of opioids for long-term management of 
chronic malignant or non-malignant pain. 
 Receiving rotating opioid medication regimens (and thus are 
at risk for incomplete cross-tolerance). 
 Discharged from emergency medical care following opioid 
intoxication or poisoning. 
 At high risk for overdose because of a legitimate medical 
need for analgesia, coupled with a suspected or confirmed 
history of substance use disorder or non-medical use of 
prescription or illicit opioids. 
 On certain opioid preparations that may increase risk for 
opioid overdose such as extended release/long-acting 
preparations. 
 Completing mandatory opioid detoxification or abstinence 
programs. 
 Recently released from incarceration and with a history of 
opioid use disorder (and presumably with reduced opioid 
tolerance and high risk of relapse to opioid use). 
It may also be advisable to suggest that the at-risk patient 
create an “overdose plan” to share with friends, partners, and/or 
caregivers. Such a plan would contain information on the signs 
of overdose and how to administer naloxone or otherwise 
provide emergency care (as by calling 911). 
DECIDE WHETHER AND WHEN TO END OPIOID 
THERAPY. Certain situations may warrant immediate cessation 
of prescribing. These generally occur when out-of-control 
behaviors indicate that continued prescribing is unsafe or 
causing harm to the patient.2 Examples include altering or selling 
prescriptions, accidental or intentional overdose, multiple 
episodes of running out early (due to excessive use), doctor 
shopping, or engaging in threatening behavior. 
When such events arise, it is important to separate the 
patient as a person from the behaviors caused by the disease of 
addiction, as by demonstrating a positive regard for the person 
but no tolerance for the aberrant behaviors. 
In such a situation, the essential steps are to (1) stop 
prescribing, (2) tell the patient that continued prescribing is not 
                                                          
clinically supportable (and thus not 
possible), (3) urge the patient to 
accept a referral for assessment by 
an addiction specialist, (4) educate 
the patient about signs and 
symptoms of spontaneous 
withdrawal and urge the patient to 
go to the emergency department if 
withdrawal symptoms occur, (5) 
retrain on the risks and the signs of 
opioid overdose and on the use of 
naloxone and consider prescribing 
naloxone if deemed appropriate, 
and (6) assure the patient that he 
or she will continue to receive care 
for the presenting symptoms or 
condition.22
Identification of a patient who is 
misusing a prescribed opioid 
presents a major therapeutic 
opportunity. The physician should 
have a plan for managing such a 
patient, typically involving work with 
the patient and the patient’s family, 
referral to an addiction expert for 
assessment and placement in a 
formal addiction treatment 
program, long-term participation in 
a 12-Step mutual-help program 
such as Narcotics Anonymous, and 
follow-up of any associated 
medical or psychiatric 
comorbidities.2
Providing training on use of 
naloxone and prescribing a 
naloxone kit or FDA-approved 
naloxone should be considered. 
In all cases, patients should be 
given the benefit of the physician’s 
concern and attention. It is 
important to remember that even 
drug-seeking patients often have 
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very real medical problems that demand and deserve the same 
high-quality medical care offered to any patient.2,22
TREATING OPIOID OVERDOSE 
In the time it takes for an overdose to become fatal, it is 
possible to reverse the respiratory depression and other effects 
of opioids through respiratory support and administration of the 
opioid antagonist naloxone. 17 Naloxone is approved by the FDA 
and has been used for decades to reverse overdose and 
resuscitate individuals who have overdosed on opioids. The 
routes of administration for naloxone are intravenous, intranasal, 
intramuscular, and subcutaneous. 
The safety profile of naloxone is remarkably high, especially 
when used in low doses and titrated to effect.6,17 If given to 
individuals who are not opioid-intoxicated or opioid-dependent, 
naloxone produces no clinical effects, even at high doses. 
Moreover, while rapid opioid withdrawal in tolerant patients may 
be unpleasant, it is not typically life-threatening. 
Naloxone should be part of an overall approach to known or 
suspected opioid overdose that incorporates the steps below. 
RECOGNIZE THE SIGNS OF OVERDOSE. An opioid 
overdose requires rapid diagnosis. The most common signs of 
overdose include2: 
 Extreme sleepiness, inability to awaken verbally or upon 
sternal rub. 
 Breathing problems that can range from slow to shallow 
breathing in a patient who cannot be awakened. 
 Fingernails or lips turning blue/purple. 
 Extremely small “pinpoint” pupils. 
 Slow heartbeat and/or low blood pressure. 
Signs of OVERMEDICATION, which may progress to overdose, 
include2: 
 Unusual sleepiness, drowsiness, or difficulty staying awake 
despite loud verbal stimulus or vigorous sternal rub. 
 Mental confusion, slurred speech, intoxicated behavior. 
 Slow or shallow breathing. 
 Pinpoint (small) pupils; normal size pupils does not exclude 
opioid overdose. 
 Slow heartbeat, low blood pressure. 
 Difficulty waking the person from sleep. 
Because opioids depress 
respiratory function and breathing, 
one telltale sign of an individual in 
a critical medical state is the “death 
rattle.” This is an exhaled breath 
with a very distinct, labored sound 
coming from the throat. It indicates 
that emergency resuscitation is 
needed immediately.26
SUPPORT RESPIRATION. 
Supporting respiration is the single 
most important intervention for 
opioid overdose and may be life-
saving on its own. Ideally, 
individuals who are experiencing 
opioid overdose should be 
ventilated with oxygen before 
naloxone is administered to reduce 
the risk of acute lung injury.2,6 In 
situations where oxygen is not 
available, rescue breathing can be 
very effective in supporting 
respiration until naloxone becomes 
available.27 Rescue breathing 
involves the following steps: 
 Verify that the airway is clear. 
 With one hand on the patient’s 
chin, tilt the head back and 
pinch the nose closed. 
 Place your mouth over the 
patient’s mouth to make a seal 
and give 2 slow breaths (the 
patient’s chest should rise, but 
not the stomach). 
 Follow up with 1 breath every 5 
seconds. 
ADMINISTER NALOXONE. 
Naloxone competitively binds 
opioid receptors and is the 
antagonist of choice for the 
reversal of acute opioid toxicity. 
Any patient who presents with 
signs of opioid overdose, or when 
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this is suspected, should be administered naloxone.9 Naloxone 
can be given intranasally intramuscularly, subcutaneously, or by 
intravenous injection.9,17,18
PREGNANT PATIENTS. Naloxone can be used in life-
threatening opioid overdose circumstances in pregnant women.9
MONITOR THE PATIENT’S RESPONSE. Patients should be 
monitored for re-emergence of signs and symptoms of opioid 
toxicity for at least 4 hours following the last dose of naloxone 
(however, patients who have overdosed on long-acting opioids 
require more prolonged monitoring).6
Most patients respond to naloxone by returning to 
spontaneous breathing, with mild withdrawal symptoms.6 The 
response generally occurs within 3 to 5 minutes of naloxone 
administration. (Continue rescue breathing while waiting for the 
naloxone to take effect.) 
The duration of effect of naloxone is 20 to 90 minutes de- 
pending on dose and route of administration. Patients should be 
observed after that time for re-emergence of overdose 
symptoms. The goal of naloxone therapy should be restoration of 
adequate spontaneous breathing, but not necessarily complete 
arousal.18,19
More than one dose of naloxone may be required to revive 
the patient. Those who have taken longer-acting opioids or 
opioid partial agonists may require further doses or may require 
further intravenous bolus doses or an infusion of naloxone.22 
Therefore, it is essential to get the person to an emergency 
department or other source of acute care as quickly as possible, 
even if he or she revives after the initial dose of naloxone and 
seems to feel better. 
SIGNS OF OPIOID WITHDRAWAL. Withdrawal triggered by 
naloxone can feel unpleasant. As a result, some persons 
become agitated or combative when this happens and need help 
to remain calm. 
The signs and symptoms of opioid withdrawal in an individual 
who is physically dependent on opioids may include (but are not 
limited to) the following: body aches, diarrhea, tachycardia, fever, 
runny nose, sneezing, piloerection, sweating, yawning, nausea 
or vomiting, nervousness, restlessness or irritability, shivering or 
trembling, abdominal cramps, weakness, and increased blood 
pressure.17 Withdrawal syndromes may be precipitated by as 
little as 0.05 to 0.2 mg intravenous naloxone in a patient taking 
24 mg per day of methadone. 
In neonates, opioid withdrawal 
may also produce convulsions, 
excessive crying, and hyperactive 
reflexes.17 Additionally, in 
neonates, opiate withdrawal may 
be life- threatening if not 
recognized and properly treated. 
NALOXONE NON-
RESPONDERS. If a patient does 
not respond to naloxone, an 
alternative explanation for the 
clinical symptoms should be 
considered. The most likely 
explanation is that the person is not 
over- dosing on an opioid but 
rather some other substance or 
may even be experiencing a non-
overdose medical emergency. 
Another possible explanation to 
consider is that the individual has 
overdosed on buprenorphine, a 
long-acting opioid partial agonist. 
Because buprenorphine has a 
higher affinity for the opioid 
receptors than do other opioids, 
naloxone may not be effective at 
reversing the effects of 
buprenorphine-induced opioid 
overdose5. 
In all cases, support of 
ventilation, oxygenation, and blood 
pressure should be sufficient to 
prevent the complications of opioid 
overdose and should be given the 
highest priority if the patient’s 
response to naloxone is not 
prompt. 
NOTE: All naloxone products have 
an expiration date. It is important to 
check the expiration date and 
obtain replacement naloxone as 
needed. 
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LEGAL AND LIABILITY 
CONSIDERATIONS 
Health care professionals who are concerned about legal risks 
associated with prescribing naloxone may be reassured by the 
fact that prescribing naloxone to manage opioid overdose is 
consistent with the drug’s FDA-approved indication, resulting in 
no increased liability so long as the prescriber adheres to 
general rules of professional conduct. Many state laws and 
regulations now permit physicians to prescribe naloxone to a 
third party, such as a caregiver.11 More information on state 
policies is available at http://www.prescribetoprevent.org or from 
individual state medical boards. 
CLAIMS CODING AND BILLING 
Most private health insurance plans, Medicare, and Medicaid 
cover naloxone for the treatment of opioid overdose, but policies 
vary by state. The cost of take-home naloxone should not be a 
prohibitive factor. Not all community pharmacies stock naloxone 
routinely, but they can always order it. If you are caring for a 
large population of patients who are likely to benefit from 
naloxone, you may wish to notify the pharmacy when you 
implement naloxone prescribing as a routine practice. 
The codes for Screening, Brief Intervention, and Referral to 
Treatment (SBIRT) can be used to bill time for counseling a 
patient about how to recognize overdose and how to administer 
naloxone. Billing codes for SBIRT are as follows: 
 Commercial Insurance: CPT 99408 (15 to 30 minutes) 
 Medicare: G0396 (15 to 30 minutes)  
 Medicaid: H0050 (per 15 minutes) 
For counseling and instruction 
on the safe use of opioids, 
including the use of naloxone 
outside of the context of SBIRT 
services, the provider should 
document the time spent in 
medication education and use the 
E&M code that accurately captures 
the time and complexity. For 
example, for new patients deemed 
appropriate for opioid 
pharmacotherapy and when a 
substantial and appropriate amount 
of additional time is used to provide 
a separate service such as 
behavioral counseling (e.g., opioid 
overdose risk assessment and 
naloxone administration training), 
consider using modifier–25 in 
addition to the E&M code. 
In addition, when using an 
evidence-based opioid use 
disorder or overdose risk factor 
assessment tool/screening 
instrument, CPT Code 99420 
(Administration and interpretation 
of health risk assessment 
instrument) can be used for 
patients with commercial 
insurance.
  
17 
 
INFORMATION FOR PRESCRIBERS  
RESOURCES FOR PRESCRIBERS 
Additional information on prescribing opioids for chronic pain is available at the following websites: 
http://www.opioidprescribing.com.  
Sponsored by the Boston University School of Medicine, with support from SAMHSA, this site presents 
course modules on various aspects of prescribing opioids for chronic pain. To view the list of courses and to 
register, go to http://www.opioidprescribing.com/overview. CME credits are available at no charge. 
http://pcss-o.org or www.pcssmat.org. Sponsored by the American Academy of Addiction Psychiatry in 
collaboration with other specialty societies and with support from SAMHSA, the Providers’ Clinical Support 
System offers multiple resources related to opioid prescribing and the diagnosis and management of opioid 
use disorder. 
http://www.er-la-opioidrems.com/IwgUI/rems/home.action. As required by the FDA under a risk management 
program for extended-release and long-acting opioid analgesics, this website provides physician training 
and patient education on the use of such medications. 
http://www.medscape.com. One course module sponsored by SAMHSA on Screening, Brief Intervention, 
and Referral to Treatment (SBIRT) can be accessed at http://www.medscape.org/viewarticle/830331. 
CME/CE credits are available at no charge. 
http://prescribetoprevent.org.  Compiled by prescribers, pharmacists, public health workers, lawyers, and 
researchers working on overdose prevention and naloxone access, this privately funded site provides 
resources to help health care providers educate their patients to reduce overdose risk and provide naloxone 
rescue kits to patients.
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WHAT ARE OPIOIDS? 
Opioids include illicit drugs such as heroin and prescription medications used to treat pain such as morphine, codeine, 
methadone, oxycodone, hydrocodone, fentanyl, 
hydromorphone, and buprenorphine. 
Opioids work by binding to specific receptors 
in the brain, spinal cord, and gastrointestinal tract. 
In doing so, they minimize the body’s perception 
of pain. However, stimulating the opioid receptors 
or “reward centers” in the brain can also trigger 
other systems of the body, such as those 
responsible for regulating mood, breathing, and 
blood pressure. 
A variety of effects can occur after a person 
takes opioids, ranging from pleasure to nausea 
and vomiting, from severe allergic reactions 
(anaphylaxis) to overdose, in which breathing and 
heartbeat slow or even stop. 
Opioid overdose can occur when a patient 
misunderstands the directions for use, 
accidentally takes an extra dose, or deliberately 
misuses a prescription opioid or an illicit drug 
such as heroin. 
Also at risk is the person who takes opioid 
medications pre- scribed for someone else, as is 
the individual who combines opioids—prescribed 
or illicit—with alcohol, certain other medications, 
and even some over-the-counter products that 
depress breathing, heart rate, and other functions 
of the central nervous system5. 
PREVENTING OVERDOSE 
If you are concerned about your own use of 
opioids, don’t wait! Talk with the health care 
professional(s) who prescribed the medications 
for you. If you are concerned about a family 
member or friend, urge him or her to talk to 
whoever prescribed the medication. 
Effective treatment of opioid use disorder can 
reduce the risk of overdose and help a person 
who is misusing or addicted to opioid medications 
attain a healthier life. An evidence-based practice 
for treating opioid addiction is the use of United 
States Food and Drug Administration (FDA)-
approved medications, along with counseling and 
other supportive services. These services are 
available at SAMHSA-certified and DEA-
registered opioid treatment programs (OTPs).28,29 
In addition, physicians who are trained to provide 
treatment for opioid addiction in office-based and 
other settings with medications such as 
buprenorphine/naloxone and naltrexone may be 
available in your community.30
IF YOU SUSPECT AN 
OVERDOSE 
An opioid overdose requires immediate 
medical attention. An essential first step is to get 
help from some- one with medical expertise as 
soon as possible. Call 911 immediately if you or 
someone you know exhibits any of the symptoms 
listed below. All you have to say: “Some- one is 
unresponsive and not breathing.” Give a clear 
address and/or description of your location. 
Signs of OVERDOSE, which is a life-
threatening emergency, include the following: 
 The face is extremely pale and/or clammy to 
the touch. 
 The body is limp. 
 Fingernails or lips have a blue or purple cast. 
 The person is vomiting or making gurgling 
noises. 
 He or she cannot be awakened from sleep or 
is unable to speak. 
 Breathing is very slow or stopped. 
 The heartbeat is very slow or stopped. 
Signs of OVERMEDICATION, which may 
progress to overdose, include: 
 Unusual sleepiness or drowsiness. 
 Mental confusion, slurred speech, or 
intoxicated behavior. 
 Slow or shallow breathing. 
 Extremely small “pinpoint” pupils. 
 Slow heartbeat or low blood pressure. 
 Difficulty in being awakened from sleep. 
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WHAT IS 
NALOXONE?  
Naloxone is an antidote to 
opioid overdose. It is an opioid 
antagonist that is used to 
reverse the effects of opioids. 
Naloxone works by blocking 
opiate receptor sites. It is not 
effective in treating overdoses of 
benzodiazepines (such as Vali- 
um®, Xanax®, or Klonopin®), 
barbiturates (Seconal® or 
Fiorinal®), clonidine, Elavil®, 
GHB, or ketamine. It is also not 
effective in treating overdoses of 
stimulants such as cocaine and 
amphetamines (including 
methamphetamine and Ecstasy). 
However, if opioids are taken in 
combination with other sedatives 
or stimulants, naloxone may be 
helpful. 
IMPORTANT SAFETY 
INFORMATION. Naloxone may 
cause dizziness, drowsiness, or 
fainting. 
These effects may be worse if it 
is taken with alcohol or certain 
medicines. For more information, 
see 
http://www.fda.gov/drugs/drugsaf
ety/postmarketdrugsafetyinforma
tionforpatientsandproviders/ucm
472923.htm.  
REPORT ANY 
SIDE EFFECTS 
Get emergency medical help 
if you or someone has any signs 
of an allergic reaction after 
taking naloxone, such as hives, 
difficulty breathing, or swelling of 
your face, lips, tongue, or throat. 
Call your doctor or 911 at once if 
you have a serious side effect 
such as: 
 Chest pain, or fast or 
irregular heartbeats. 
 Dry cough, wheezing, or 
feeling short of breath. 
 Sweating, severe nausea, or 
vomiting. 
 Severe headache, agitation, 
anxiety, confusion, or ringing 
in your ears. 
 Seizures (convulsions). 
 Feeling that you might pass 
out. 
 Slow heart rate, weak pulse, 
fainting, or slowed breathing. 
If you are being treated for 
opioid use disorder (either an 
illicit drug like heroin or a 
medication prescribed for pain), 
you may experience the 
following symptoms of opioid 
withdrawal after taking naloxone: 
 Feeling nervous, restless, or 
irritable. 
 Body aches. 
 Dizziness or weakness. 
 Diarrhea, stomach pain, or 
mild nausea. 
 Fever, chills, or 
goosebumps. 
 Sneezing or runny nose in 
the absence of a cold. 
This is not a complete list of 
side effects, and others may 
occur. Talk to your doctor about 
side effects and how to deal with 
them. 
STORE 
NALOXONE IN A 
SAFE PLACE 
Naloxone is usually handled and 
stored by a health care provider. 
If you are using naloxone at 
home, store it in a locked cabinet 
or other space that is out of the 
reach of children or pets. 
SUMMARY: 
HOW TO AVOID 
OPIOID 
OVERDOSE 
1. Take medicine only if it has 
been prescribed to you by 
your doctor. 
2. Do not take more medicine 
or take it more often than 
instructed. 
3. Call a doctor if your pain 
gets worse. 
4. Never mix pain medicines 
with alcohol, sleeping pills, 
or any illicit substance. 
5. Store your medicine in a 
safe place where children or 
pets can- not reach it. 
6. Learn the signs of overdose 
and how to use naloxone to 
keep it from becoming fatal. 
7. Teach your family and 
friends how to respond to an 
overdose. 
8. Dispose of unused 
medication properly. 
READ MORE AT 
http://www.fda.gov/drugs/drugsafety/p
ostmarketdrugsafetyinformationforpati
entsandproviders/ucm472923.htm.
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RESOURCES FOR OVERDOSE 
SURVIVORS AND FAMILY MEMBERS 
Survivors of opioid overdose have experienced a life- changing and traumatic event. They have had to deal with the emotional consequences of overdosing, which can involve 
embarrassment, guilt, anger, and gratitude, all accompanied by the 
discomfort of opioid withdrawal. Most need the support of family and 
friends to take the next steps toward recovery. 
While many factors can contribute to opioid overdose, it is al- 
most always an accident. Moreover, the underlying problem that led 
to opioid use—most often pain or substance use disorder—still exists 
and continues to require attention.2
Moreover, the individual who has experienced an overdose is not 
the only one who has endured a traumatic event. Family members 
often feel judged or inadequate because they could not prevent the 
overdose. It is important for family members to work together to help 
the overdose survivor obtain the help that he or she needs. 
FINDING A NETWORK OF SUPPORT 
As with any disease, it is not a sign of weakness to admit that a 
person or a family cannot deal with the trauma of overdose with- out 
help. It takes real courage to reach out to others for support and to 
connect with members of the community to get help. 
Health care providers, including those who specialize in treating 
substance use disorders, can provide structured, therapeutic support 
and feedback. 
If the survivor’s underlying problem is pain, referral to a pain 
specialist may be in order. If it is addiction, the patient should be 
referred to an addiction specialist for assessment and treatment, 
either by a physician specializing in the treatment of opioid addiction, 
in a residential treatment program, or in a federally certified Opioid 
Treatment Program (OTP). In each case, counseling can help the 
individual manage his or her problems in a healthier way. Choosing 
the path to recovery can be a dynamic and challenging process, but 
there are ways to help.
In addition to receiving support 
from family and friends, 
overdose survivors can access 
a variety of community-based 
organizations and institutions, 
such as: 
 Health care and behavioral 
health providers. 
 Peer-to-peer recovery 
support groups such as 
Narcotics Anonymous. 
 Faith-based organizations. 
 Educational institutions. 
 Neighborhood groups. 
 Government agencies. 
 Family and community 
support programs. 
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RESOURCES 
Information on opioid overdose and helpful advice for overdose survivors and their families can be found at: 
Substance Abuse and Mental Health Services Administration (SAMHSA) 
 National Helpline 1-800-662-HELP (4357) or 1-800-487-4889  
(TDD—for hearing impaired) 
 Behavioral Health Treatment Services Locator: https://findtreatment.samhsa.gov to search by 
address, city, or zip code 
 Buprenorphine Treatment Physician Locator: http://www.samhsa.gov/medication-assisted-
treatment/physician-program-data/treatment-physician-locator  
 State Substance Abuse Agencies: 
https://findtreatment.samhsa.gov/TreatmentLocator/faces/about.jspx 
Centers for Disease Control and Prevention (CDC): 
http://www.cdc.gov/drugoverdose/epidemic 
National Institutes of Health (NIH), National Center for Biotechnical Information:  
http://www.ncbi.nlm.nih.gov 
Partnership for Drug-Free Kids: 
http://www.drugfree.org/join-together/opioid-overdose-antidote-being-more-widely-distributed-to-those-
who-use-drugs  
Project Lazarus:  
http://www.projectlazarus.org  
Harm Reduction Coalition:  
http://www.harmreduction.org  
Overdose Prevention Alliance: 
http://www.overdosepreventionalliance.org  
Toward the Heart:  
http://www.towardtheheart.com/naloxne 
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